Global Schistosomiasis Treatment Market , By Site (Intestinal, Urogenital), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Type (Schistosoma Mansoni, Schistosoma Japonicum, Schistosoma Mekongi, Schistosoma Guineensis, Schistosoma Haematobium, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Schistosomiasis Treatment Market Analysis and Size
The global schistosomiasis treatment market is expected to witness significant growth during the forecast period. As per the World Health Organization (WHO) records in 2017, urogenital schistosomiasis is a major risk factor for the transmission of HIV infection in women. People generally get infected during agriculture, domestic, and occupational activities, which exposes them to infected water resulting into immune reactions. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global schistosomiasis treatment market in the forecast period 2022-2029. The expected CAGR of global nasal polyposis drugs market is tend to be around 4% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Schistosomiasis is also known as snail fever and bilharzia that is defined as protozoan infections caused by flateworm schistosomes affecting the urinary tract or the intestines. It is spread by closed contact with dirty hands of contaminated food, fluid and marked by headaches, muscle aches and itchy skin. There are two types of schistosomiasis, such as intestinal and urogenital. Symptoms include various symptoms such as, fibrosis of the bladder, abdominal pain, diarrhea, liver and spleen enlargement, and progressive damage of kidney.
Schistosomiasis Treatment Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Site (Intestinal, Urogenital), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Type (Schistosoma Mansoni, Schistosoma Japonicum, Schistosoma Mekongi, Schistosoma Guineensis, Schistosoma Haematobium, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (U.S.), Merck KGaA (Germany), Sanofi (France), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (India), Strides Pharma Science Limited. (India), Edenbridge Pharmaceuticals, LLC (U.S.), Zydus Healthcare Limited (India)
Global Schistosomiasis Treatment Market Dynamics
- Development of Novel Vaccines
As per the University of Nottingham in 2017, scientists have discovered the infiltrin protein on a parasitic egg, that may be responsible for this infectious disease. This discovery for targeted development of vaccination and treatments will drive the market growth. Furthermore, the College of Science at Oregon State University (OSU), discovered the new protein in Biomphalaria glabrata snail, which is known as Grctm6 in 2017. Researchers use this protein as a biocontrol agent against schistosomiasis. This boosts the market growth.
- Varied Treatment Options
Diversified treatment options for treating schistosomiasis patients are boosting the market's growth. Praziquantel drug is used to treat schistosomiasis and is more effective on adult worms; but, no effective medication is available in the market for eggs or immature worms. Other than that, corticosteroids are also used to treat the disease. Surgical alternatives can include the removal of tumors, shunt surgeries, and granuloma removal. This factor propel the growth of the market.
- Increasing Demand for Chemotherapy
As per the records of WHO in 2017, around 92% people require preventive chemotherapy for schistosomiasis in Africa. About 75% of school aged children are at higher risk of morbidity from schistosomiasis and soil-transmitted helminthiasis. Additionally, 78% of the economies have an epidemic outbreak of schistosomiasis and around 52% of those countries require preventive chemotherapy. Also, globally 207.7 million people required preventive chemotherapy in 2016, wherein around 111.8 million were school-aged children.
- Increasing Awareness About The Disease
Rising awareness about the diseased condition among patients and doctors leads to the market expansion. For instance, in May 2017, Global Schistosomiasis Alliance organized the world’s Neglected tropical diseases (NTDs) program which WHO hosted. Numerous organizations from several economies supported this schistosomiasis control initiative program, that include Swiss Tropical and Public Health Institute, Chinese Centers for Disease Control and Prevention (CDC), Research for Control and Elimination (SCORE), The Federal Ministry of Health Ethiopia (FMHE), and The Ministry of Health (MoH).
- Lack of skilled professionals
The lack of qualified healthcare professionals who are unable to treat these patients with appropriate treatments could restrain the growth of the global schistosomiasis treatment market over a forecast period.
- Lack of safe drinking water
Even though schistosomiasis is not transmitted by swallowing contaminated water, but if the mouth or lips comes in contact with water that contain the parasites, one could become infected. Absence of safe water for bathing, poor sanitation, washing and swimming, and hygiene practices were major risk factors for schistosomiasis.Thus, all these factors hamper the market growth.
This global schistosomiasis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global schistosomiasis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Schistosomiasis Treatment Market Scope
The global schistosomiasis treatment market is segmented on the basis of drugs, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Schistosoma Mansoni
- Schistosoma Japonicum
- Schistosoma Mekongi
- Schistosoma Guineensis
- Schistosoma Haematobium
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Schistosomiasis Treatment Market Regional Analysis/Insights
The global schistosomiasis treatment market is analysed and market size insights and trends are provided by drugs, type, distribution channel and end-user as referenced above.
The major countries covered in the global schistosomiasis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global schistosomiasis treatment market throughout the forecasted period due to the growing cases of protozoan infections, developing healthcare facilities and presence of generic companies.
North America dominates the market due to the high diagnostic rate and presence of sophisticated medical facilities in order to maximize the treatment effectiveness for patient and increases focuses in the research and development activity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Schistosomiasis Treatment Market Share Analysis
The global schistosomiasis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global schistosomiasis treatment market
Key players operating in the global schistosomiasis treatment market include:
- Pfizer Inc.(U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- Lilly (U.S.)
- Teva Pharmaceutical Industries (Israel)
- Mitsubishi Chemical Group Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- AstraZeneca (India)
- Strides Pharma Science Limited. (India)
- Edenbridge Pharmaceuticals, LLC (U.S.)
- Zydus Healthcare Limited (India)